First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

K Lindemann; R D Christensen; I Vergote; G Stuart; M A Izquierdo; J Kærn; H Havsteen; E Eisenhauer; M Ridderheim; A B Lopez; H Hirte; E Aavall-Lundquvist; E Vrdoljak; J Green; G B Kristensen

doi:10.1093/annonc/mds060

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

K Lindemann
, R D Christensen
, I Vergote
, G Stuart
, M A Izquierdo
, J Kærn
, H Havsteen
, E Eisenhauer
, M Ridderheim
, A B Lopez
, H Hirte
, E Aavall-Lundquvist
, E Vrdoljak
, J Green
, G B Kristensen

Department of Oncology

31 Citations (Scopus)

Abstract

The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.

Original language	English
Journal	Annals of Oncology
Volume	23
Issue number	10
Pages (from-to)	2613-9
Number of pages	7
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mds060
Publication status	Published - 2012

Access to Document

10.1093/annonc/mds060

Cite this

Lindemann, K., Christensen, R. D., Vergote, I., Stuart, G., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Aavall-Lundquvist, E., Vrdoljak, E., Green, J., & Kristensen, G. B. (2012). First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Annals of Oncology, 23(10), 2613-9. https://doi.org/10.1093/annonc/mds060

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. / Lindemann, K; Christensen, R D; Vergote, I et al.
In: Annals of Oncology, Vol. 23, No. 10, 2012, p. 2613-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Lindemann, K, Christensen, RD, Vergote, I, Stuart, G, Izquierdo, MA, Kærn, J, Havsteen, H, Eisenhauer, E, Ridderheim, M, Lopez, AB, Hirte, H, Aavall-Lundquvist, E, Vrdoljak, E, Green, J & Kristensen, GB 2012, 'First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG', Annals of Oncology, vol. 23, no. 10, pp. 2613-9. https://doi.org/10.1093/annonc/mds060

@article{c7ac684a3812452ebccd164de9af11f8,

title = "First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG",

abstract = "The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.",

author = "K Lindemann and Christensen, \{R D\} and I Vergote and G Stuart and Izquierdo, \{M A\} and J K{\ae}rn and H Havsteen and E Eisenhauer and M Ridderheim and Lopez, \{A B\} and H Hirte and E Aavall-Lundquvist and E Vrdoljak and J Green and Kristensen, \{G B\}",

year = "2012",

doi = "10.1093/annonc/mds060",

language = "English",

volume = "23",

pages = "2613--9",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

AU - Lindemann, K

AU - Christensen, R D

AU - Vergote, I

AU - Stuart, G

AU - Izquierdo, M A

AU - Kærn, J

AU - Havsteen, H

AU - Eisenhauer, E

AU - Ridderheim, M

AU - Lopez, A B

AU - Hirte, H

AU - Aavall-Lundquvist, E

AU - Vrdoljak, E

AU - Green, J

AU - Kristensen, G B

PY - 2012

Y1 - 2012

N2 - The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.

AB - The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival of adding epirubicin to standard carboplatin and paclitaxel.

U2 - 10.1093/annonc/mds060

DO - 10.1093/annonc/mds060

M3 - Journal article

C2 - 22539562

SN - 0923-7534

VL - 23

SP - 2613

EP - 2619

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

Abstract

Access to Document

Fingerprint

Cite this